Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

BACKGROUND: This study evaluated the cost-effectiveness of replacing standard intravenous therapy (taxane) with oral S-1 therapy for first-line metastatic breast cancer treatment. METHODS: This cost-effectiveness analysis was based on data from a randomized phase III trial (SELECT BC). As cost-effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiroiwa, Takeru, Fukuda, Takashi, Shimozuma, Kojiro, Mouri, Mitsuko, Hagiwara, Yasuhiro, Kawahara, Takuya, Ohsumi, Shozo, Hozumi, Yasuo, Sagara, Yoshiaki, Ohashi, Yasuo, Mukai, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693567/
https://www.ncbi.nlm.nih.gov/pubmed/29149882
http://dx.doi.org/10.1186/s12885-017-3774-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693567/
https://www.ncbi.nlm.nih.gov/pubmed/29149882
http://dx.doi.org/10.1186/s12885-017-3774-7

Ejemplares similares